FDA-approved1,2Evidence: Smaller human trialsGut and digestion

Teduglutide1

Also called Gattex1,2

Key takeaway

Teduglutide is a lab-made analogue of glucagon-like peptide-2 (GLP-2), a gut hormone that supports the lining of the intestine, and is the active ingredient in Gattex.1,2 FDA approved Gattex in 2012 for short bowel syndrome in people who depend on parenteral support, nutrition or fluids given through a vein. It is approved for adults and for children 1 year and older.1,2 In a randomized, placebo-controlled trial of 86 adults, 63% on teduglutide cut their weekly parenteral support by at least a fifth, versus 30% on placebo. The label warns that it may speed the growth of existing tumors.1

Teduglutide at a glance

What it isAn analogue of human GLP-2 that binds GLP-2 receptors in the intestine, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Gattex with an original approval date of December 21, 2012. The cited label has no boxed warning.1,2
Human evidenceA randomized, double-blind, placebo-controlled trial in 86 adults with short bowel syndrome and its two-year open-label extension, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is teduglutide?

Teduglutide is a synthetic analogue of glucagon-like peptide-2 (GLP-2), a peptide released by cells of the lower intestine.1

In the United States it is the active ingredient of Gattex, from Takeda, according to Drugs@FDA.2

How does teduglutide work?

The label states that GLP-2 increases blood flow to the intestine and reduces stomach acid, and that teduglutide binds GLP-2 receptors on cells and nerves in the intestinal wall.1

The label states that activating these receptors releases several local signalling molecules in the intestinal wall.1

What do human studies show?

In Study 1, 86 adults with short bowel syndrome were randomized to teduglutide or placebo. At weeks 20 and 24, 63% (27 of 43) on teduglutide and 30% (13 of 43) on placebo had at least a 20% reduction in weekly parenteral support, according to the label.1

In the open-label extension, 28 of 30 patients who completed 30 months of treatment had at least a 20% reduction, and 10 no longer needed parenteral support, according to the label.1

The label also describes a second placebo-controlled trial in adults (Study 3) and two studies in which 41 children aged 1 to under 17 received it.1

What the evidence base contains

  • Controlled human trial Study 1 (NCT00798967): a randomized, double-blind, placebo-controlled trial in 86 adults with short bowel syndrome dependent on parenteral support, described in the label.1
  • Small, short, or incompletely reported human study Study 2 (NCT00930644): a two-year open-label extension of Study 1 in 88 adults, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is teduglutide FDA-approved?

Yes. Drugs@FDA lists Gattex, application NDA 203441, with an original approval date of December 21, 2012.2

The Gattex label cited here (DailyMed SPL version 20, published September 18, 2025) states that it is indicated for adults and children 1 year and older with short bowel syndrome who are dependent on parenteral support.1

The label has no boxed warning. Its warnings include possible acceleration of tumor growth, with colon screening recommended, intestinal obstruction, gallbladder, bile duct and pancreas disease, and fluid overload.1

Timeline

  1. FDA approves Gattex, according to Drugs@FDA.2
  2. DailyMed publishes the Gattex label version cited on this page.1

What is still unknown?

Its long-term tumor risk, which the label addresses with a warning and recommended screening rather than settled data.1

Which patients will be able to stop parenteral support entirely: in the extension, 10 of 30 long-term patients did.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Teduglutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Teduglutide are a bounded selection, not every registration or paper about Teduglutide. For the years before Teduglutide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Teduglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Teduglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Gattex for short bowel syndrome. A randomized, placebo-controlled trial of 86 adults described in the label found that more patients reduced parenteral support with teduglutide. The label warns of possible acceleration of tumor growth.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Teduglutide?

FDA-approved as Gattex for short bowel syndrome. A randomized, placebo-controlled trial of 86 adults described in the label found that more patients reduced parenteral support with teduglutide. The label warns of possible acceleration of tumor growth.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
12
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date September 8, 2026

ClinicalTrials.gov record NCT06973304↗Added to PeptideScanner November 15, 2026

Collection changes

What did PeptideScanner add most recently?

  1. Clinical trials · added November 15, 2026

    ClinicalTrials.gov record NCT06973304↗Source date September 8, 2026
  2. Literature metadata · added November 15, 2026

    Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study.↗Source date February 8, 2026
  3. Literature metadata · added November 15, 2026

    Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).↗Source date January 27, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Teduglutide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

58Selected dated records
60Connected citations
12Populated source years2012–2026
3/4Record lanes present

Registered human studies

Trial composition

30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 3 17Phase 2 7Phase 1 5Phase 4 2Early Phase 1 1
Status at observationCompleted 29Active, not recruiting 1

PubMed bibliography

Publication composition

24 of 24 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 22Case Reports 8Review 5Research Support, Non-U.S. Gov't 4Clinical Trial, Phase III 1Comment 1Consensus Statement 1Editorial 1Letter 1Multicenter Study 1Observational Study 1Randomized Controlled Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
3
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
58

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 58 dated records

Research hub

Explore the Teduglutide evidence record

Open all 58 records →
58Dated records
3Evidence types
58Cited public sources
12Source years

Change ledger

Recently changed for Teduglutide

Open all 58 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00072839

PeptideScanner retained ClinicalTrials.gov record NCT00072839 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-25, and PeptideScanner's reviewed identity mapping was teduglutide.

PeptideScanner change date
November 15, 2026
Cited source date
May 25, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00081458

PeptideScanner retained ClinicalTrials.gov record NCT00081458 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.

PeptideScanner change date
November 15, 2026
Cited source date
June 9, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00172185

PeptideScanner retained ClinicalTrials.gov record NCT00172185 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was teduglutide.

PeptideScanner change date
November 15, 2026
Cited source date
June 2, 2021
Evidence lane
Clinical trials

Official-source collections

Source records for Teduglutide

Open the full research atlas →
PubMed24

24 with attributed title, venue, publication-date, and type metadata.

  1. Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.BMJ open gastroenterology · 2025 08 05
  2. Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report.Frontiers in nutrition · 2025 07 23
  3. Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide.Endocrinologia, diabetes y nutricion · 2025 Mar
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06973304Registry update September 8, 2026 · current at observation
  2. NCT03562130Registry update September 11, 2025 · completed at observation
  3. NCT02949362Registry update March 19, 2025 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span May 7, 2012 to September 8, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 58

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06973304↗

    PeptideScanner retained ClinicalTrials.gov record NCT06973304 at 2026-11-15T21:55:23.600Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was teduglutide.↗

  2. Literature metadata

    Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study.↗

    PubMed lists PMID 41647102 in Intestinal Failure (New York, N.Y.) as Journal Article, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).↗

    PubMed lists PMID 35654733 in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver as Journal Article, Review, Consensus Statement, with publication-date metadata of 2022-05-31 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy.↗

    PubMed lists PMID 36177820 in Revista espanola de enfermedades digestivas as Case Reports, Journal Article, with publication-date metadata of 2023-06 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.↗

    PubMed lists PMID 37001195 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, with publication-date metadata of 2023-03-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring.↗

    PubMed lists PMID 37270288 in The American journal of clinical nutrition as Journal Article, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.↗

    PubMed lists PMID 40764045 in BMJ open gastroenterology as Journal Article, with publication-date metadata of 2025-08-05 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT03562130↗

    PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide.↗

  9. Literature metadata

    Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report.↗

    PubMed lists PMID 40771220 in Frontiers in nutrition as Case Reports, Journal Article, with publication-date metadata of 2025-07-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide.↗

    PubMed lists PMID 40086997 in Endocrinologia, diabetes y nutricion as Case Reports, Journal Article, Review, with publication-date metadata of 2025-03 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT02949362↗

    PeptideScanner retained ClinicalTrials.gov record NCT02949362 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-03-19, and PeptideScanner's reviewed identity mapping was teduglutide.↗

  12. Literature metadata

    Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry.↗

    PubMed lists PMID 39125394 in Nutrients as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    GATTEX (teduglutide) kit · SPL version 20 · published 2025-09-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: GATTEX (teduglutide), NDA 203441 · original approval December 21, 2012 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026